Published in Lancet on September 12, 1981
Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol (1982) 2.49
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol (1982) 1.95
Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. Br J Clin Pharmacol (1984) 1.30
Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man. Br J Clin Pharmacol (1984) 1.10
Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure. Br Heart J (1983) 1.07
Effective dose range of enalapril in mild to moderate essential hypertension. Br J Clin Pharmacol (1985) 1.05
Antihypertensive effect of single doses of enalapril in hypertensive patients treated with bendrofluazide. Br J Clin Pharmacol (1987) 0.96
An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol (1984) 0.91
Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension. Br J Clin Pharmacol (1984) 0.90
Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients. Br J Clin Pharmacol (1984) 0.86
Natriuretic effect and changes in renal haemodynamics induced by enalapril in essential hypertension. Drugs (1985) 0.85
Enalapril in essential hypertension: a comparative study with propranolol. Enalapril in Hypertension Study Group (UK). Br J Clin Pharmacol (1984) 0.84
Comparison of the transplacental transfer of enalapril, captopril and losartan in sheep. Br J Pharmacol (1995) 0.80
New developments in renin and hypertension. BMJ (1991) 0.80
Effects of repeated doses of enalapril on renal function in man. Br J Clin Pharmacol (1985) 0.79
Blood pressure response to conventional and low-dose enalapril in chronic renal failure. Br J Clin Pharmacol (2003) 0.77
Enalapril in essential hypertension. Drugs (1985) 0.75
Comparison of monotherapy with enalapril and atenolol in mild to moderate hypertension. The Canadian Enalapril Study Group. CMAJ (1987) 0.75
The effect of enalapril on serum prolactin. Br J Clin Pharmacol (1983) 0.75
"Scalded mouth" caused by angiotensin-converting-enzyme inhibitors. Br Med J (Clin Res Ed) (1982) 0.75
Angiotensin-converting enzyme (ACE) inhibition. Therapeutic option for diabetic hypertensive patients. Drugs (1990) 0.75
Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study. Hypertension (2000) 8.84
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS (2001) 5.52
Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med (1978) 5.04
Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med (1972) 4.80
Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ (2001) 4.66
Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med (1972) 3.73
Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V Consensus Guidelines. Am J Hypertens (1994) 2.91
A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet (1977) 2.90
Comparative bioavailability of three brands of ampicillin. Can Med Assoc J (1972) 2.87
Concordance of murine quantitative trait loci for salt-induced hypertension with rat and human loci. Genomics (2001) 2.50
Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol (1982) 2.49
Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol (1987) 2.36
Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med (1979) 2.31
Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med (1972) 2.10
Cardioprotective potential of angiotensin converting enzyme inhibitors. J Hypertens (1991) 2.06
European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens (2010) 2.06
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol (1982) 1.95
Improvement of chronic congestive heart-failure by oral captopril. Lancet (1979) 1.94
Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens (2003) 1.93
Influence of oscillatory and unidirectional flow environments on the expression of endothelin and nitric oxide synthase in cultured endothelial cells. Arterioscler Thromb Vasc Biol (1998) 1.92
Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol (1981) 1.88
Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther (1981) 1.88
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens (2001) 1.87
Knowledge, attitudes, and practices on hypertension in a country in epidemiological transition. Hypertension (1998) 1.87
Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med (1998) 1.83
An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med (1974) 1.82
Angiotensin II receptor antagonists. Lancet (2000) 1.82
Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension (1980) 1.81
Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens (2001) 1.80
Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure. Lancet (1973) 1.78
Endothelial function in chronic congestive heart failure. Am J Cardiol (1992) 1.69
Conduit artery compliance and distensibility are not necessarily reduced in hypertension. Hypertension (1992) 1.64
Pharmacokinetics and comparative pharmacology of cefoxitin and cephalosporins. Rev Infect Dis (1989) 1.60
Angiotensin inhibition and malignancies: a review. J Hum Hypertens (2009) 1.59
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther (2009) 1.57
Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers. J Cardiovasc Pharmacol (1987) 1.56
Fatal pancytopenia associated with the use of captopril. Ann Intern Med (1981) 1.54
Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol (1983) 1.54
Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med (1979) 1.53
The place of angiotensin-converting enzyme inhibition in the treatment of cardiovascular diseases. N Engl J Med (1988) 1.49
A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.48
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol (2006) 1.46
Bioavailability and pharmacokinetics of cefoxitin sodium. J Antimicrob Chemother (1978) 1.46
Effect of furosemide on antibiotic-induced renal damage in rats. J Infect Dis (1972) 1.46
Insulin infusion in conscious dogs. Effects on systemic and coronary hemodynamics, regional blood flows, and plasma catecholamines. J Clin Invest (1982) 1.46
The influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects. J Clin Invest (1970) 1.42
Models of experimental hypertension in mice. Hypertension (1996) 1.41
Does the activation of poly (ADP-ribose) synthetase mediate tissue injury in the sepsis induced by cecal ligation and puncture? Shock (2001) 1.41
Muscle glycogenolysis during exercise: dual control by epinephrine and contractions. Am J Physiol (1982) 1.40
Suppressing sympathetic activation in congestive heart failure. A new therapeutic strategy. Hypertension (1995) 1.40
[Antihypertensive agents used as first line agents: beta-blockers under pressure]. Rev Med Suisse (2006) 1.39
Serotonergic excitatory drive to hypoglossal motoneurons in the decerebrate cat. Neurosci Lett (1992) 1.38
Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet (1971) 1.37
Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol (1987) 1.37
Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation (1981) 1.35
Enalapril worldwide experience. Am J Med (1984) 1.33
Vasoactive potential of the b(1) bradykinin receptor in normotension and hypertension. Circ Res (2001) 1.32
Microangiopathic haemolytic anaemia and the pathogenesis of malignant hypertension. Lancet (1969) 1.31
Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation (1978) 1.30
Angiotensin II, vasopressin, and sympathetic activity in conscious rats with endotoxemia. Am J Physiol (1985) 1.29
Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res (1975) 1.27
Synergistic effects of fluid shear stress and cyclic circumferential stretch on vascular endothelial cell morphology and cytoskeleton. Arterioscler Thromb Vasc Biol (1995) 1.25